Scholar Rock (SRRK) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Does the media favor ASND or SRRK?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Ascendis Pharma A/S and 1 mentions for Scholar Rock. Ascendis Pharma A/S's average media sentiment score of 1.20 beat Scholar Rock's score of 0.61 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in ASND or SRRK?

91.1% of Scholar Rock shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts rate ASND or SRRK?

Ascendis Pharma A/S currently has a consensus price target of $220.67, indicating a potential upside of 27.48%. Scholar Rock has a consensus price target of $42.67, indicating a potential upside of 20.02%. Given Ascendis Pharma A/S's higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Is ASND or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -93.22%. Ascendis Pharma A/S's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-93.22%	N/A	-33.29%
Scholar Rock	N/A	-118.22%	-82.01%

Which has preferable valuation and earnings, ASND or SRRK?

Scholar Rock has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$393.54M	26.89	-$409.12M	-$6.28	-27.56
Scholar Rock	$33.19M	101.70	-$246.29M	-$2.53	-14.05

Which has more risk and volatility, ASND or SRRK?

Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Summary

Ascendis Pharma A/S beats Scholar Rock on 9 of the 17 factors compared between the two stocks.